Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

169.18USD
23 Sep 2014
Price Change (% chg)

$3.06 (+1.84%)
Prev Close
$166.12
Open
$166.95
Day's High
$171.11
Day's Low
$164.38
Volume
4,302,731
Avg. Vol
1,913,896
52-wk High
$174.49
52-wk Low
$88.34

Search Stocks

Latest Key Developments (Source: Significant Developments)

Pershing Square Capital Management LP, Valeant Pharmaceuticals International Inc and Allergan Inc settle pending litigation before Delaware Court of Chancery
Tuesday, 16 Sep 2014 01:39am EDT 

Pershing Square Capital Management LP and Valeant Pharmaceuticals International Inc:Announce agreement with Allergan Inc to settle pending litigation before Delaware Court of Chancery.Pursuant to settlement, Allergan has agreed to unconditionally call and hold special meeting of its shareholders on Dec. 18, 2014.Shareholders of record at close of business on Oct. 30, will be entitled to receive notice of and vote at meeting.Shareholders who submitted special meeting requests will not be required to provide updated information to the company in advance of meeting.Pershing Square has delivered requests calling for special meeting from 51 institutions representing 35.68 pct. of outstanding common stock of Allergan.  Full Article

Allergan Inc reaffirms FY 2016 EPS guidance
Thursday, 11 Sep 2014 08:30pm EDT 

Allergan Inc:Estimates FY 2016 EPS at about $10.00.  Full Article

Allergan announces OZURDEX approved in European Union for Treatment of Diabetic Macular Edema
Tuesday, 2 Sep 2014 08:00am EDT 

Allergan Inc:Says the European Commission has extended Marketing Authorization for OZURDEX((reg))(dexamethasone 700 mcg intravitreal implant in applicator).To treat adult patients with visual impairment due to diabetic macular edema (DME) who are pseudophakic, or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.DME is common complication with diabetes and is cause of sight loss in patients with diabetes.(2,3,4).Safety and efficacy of OZURDEX((reg))in the management of patients with DME was assessed in the MEAD (Macular Edema: Assessment of Implantable Dexamethasone in Diabetes) clinical trial program.(1,5).MEAD consisted of two multi-center 3-year sham-controlled, masked, randomized clinical studies assessing the proportion of patients with 15 or more letters improvement in best-corrected visual acuity (BCVA) from baseline.Developed for treatment of retinal disease, OZURDEX((reg))implant uses proprietary innovative NOVADUR((reg))solid polymer delivery system - a biodegradable implant that releases medicine over an extended period of time - to suppress inflammation, which plays key role in the development of DME.OZURDEX((reg))is already available throughout European Union as treatment licensed for macular edema in patients with retinal vein occlusion (RVO) and for inflammation of the posterior segment of eye characterized as non-infectious uveitis.  Full Article

Allergan Inc to request California Federal Court block valeant and pershing square from voting shares acquired in violation of insider trading laws
Tuesday, 26 Aug 2014 07:53pm EDT 

Allergan Inc:Says that it has asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction.Says injunction against Valeant Pharmaceuticals, Pershing Square Capital Management, L.P. and its principal, William A. Ackman, for violations of the federal securities laws.Says in addition, Allergan announced that it will hold a Special Meeting of Stockholders on Dec. 18, 2014.Allergan has established an Oct. 27, 2014 record date for stockholders entitled to vote at the Special Meeting.  Full Article

Allergan Inc names Jim Hindman chief financial officer
Monday, 18 Aug 2014 09:00am EDT 

Allergan Inc:Says Jim Hindman has been named Executive Vice President, Finance and Business Development, Chief Financial Officer, effective immediately.Hindman succeeds Jeff Edwards, who has decided to step down from the position due to family commitment.  Full Article

Valeant Pharmaceuticals International Inc offer to acquire Allergan
Friday, 15 Aug 2014 05:00pm EDT 

Valeant Pharmaceuticals International Inc:Announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan Inc to Dec. 31.  Full Article

Allergan Inc files lawsuit in Federal Court against Valeant and Pershing Square
Friday, 1 Aug 2014 11:30am EDT 

Allergan Inc:Files lawsuit in the United States District Court for the Central District of California against Valeant Pharmaceuticals International, Inc. (Valeant), Pershing Square Capital Management, L.P. (Pershing Square) and principal, William A. Ackman.Alleges that Valeant, Pershing Square and Ackman violated federal securities laws prohibiting insider trading, engaged in other fraudulent practices, and failed to disclose legally required information.  Full Article

Allergan announces OZURDEX receives european positive opinion for the treatment of Diabetic Macular Edema
Friday, 25 Jul 2014 07:55am EDT 

Allergan Inc:Says the European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ) (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.CHMP is the scientific committee of the European Medicines Agency (EMA) that recommends medicines for Marketing Authorization across the 28 member states of the European Union.  Full Article

Allergan Inc raises FY 2014 outlook; gives FY 2015, 2016 EPS outlook above analysts' estimates; gives Q3 2014 outlook in line with analysts' estimates; gives charge outlook
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Sees FY 2014 EPS between $5.74 and $5.80.Sees FY 2015 EPS between $8.20 and $8.40.Sees FY 2016 EPS at about $10.00.Expects to incur total non-recurring pre-tax charges of between $375 and $425 million in connection with the restructuring and other costs.Sees FY 2014 total product net sales between $6.90 and $7.05 bln excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 total product net sales between $1.675 and $1.750 bln, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 non-GAAP diluted earnings per share between $1.44 and $1.47.FY 2014 EPS $5.70 and revenue of $6.98 bln - Thomson Reuters I/B/E/S.FY 2015 EPS $6.85 - Thomson Reuters I/B/E/S.FY 2016 EPS $8.14 - Thomson Reuters I/B/E/S.Q3 2014 EPS $1.45 and revenue of $1.72 bln - Thomson Reuters I/B/E/S.  Full Article

Allergan declares second quarter dividend
Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Declares second quarter dividend of $0.05 per share.Payable on Sept. 5 to stockholders of record on Aug. 15.  Full Article

Deals of the day- Mergers and acquisitions

(Adds Deere, Pfizer, Pershing Square Capital Management, Spirit Pub, Alstom, Procter & Gamble, Total, ZF Friedrichshafen, WSE, Jost Group, Grupo Oi, Eurobank Ergasias, UniCredit and Telefonica)

Search Stocks